Table 5

Five-year costs per patient according to prophylactic regimen

Netherlands Intermediate-doseSweden High-dosePNetherlands Intermediate-doseSweden High-doseP
Mean (SD), US$1000Median (IQR), US$1000
Direct costs       
Factor use 867 (380) 1452 (483) <.01 851 (647-1046) 1474 (1154-1776) <.01 
Other health care 5 (9) 4 (6) .28 2 (2-3) 1 (1–3) <.01 
Indirect costs       
Lost production 14 (50) 1 (3) .08 0 (0-0)* 0 (0-0)* .82 
Total costs 886 (382) 1457 (484) <.01 852 (659-1094) 1475 (1155-1787) <.01 
Netherlands Intermediate-doseSweden High-dosePNetherlands Intermediate-doseSweden High-doseP
Mean (SD), US$1000Median (IQR), US$1000
Direct costs       
Factor use 867 (380) 1452 (483) <.01 851 (647-1046) 1474 (1154-1776) <.01 
Other health care 5 (9) 4 (6) .28 2 (2-3) 1 (1–3) <.01 
Indirect costs       
Lost production 14 (50) 1 (3) .08 0 (0-0)* 0 (0-0)* .82 
Total costs 886 (382) 1457 (484) <.01 852 (659-1094) 1475 (1155-1787) <.01 

IQR, interquartile range; SD, standard deviation.

*

Ninetieth percentile values were US$30 vs US$2 for Netherlands and Sweden, respectively, in US$1000. Mean costs are influenced by outliers but reflect the total budget at group level, and median costs reflect the cost of the middle person in a skewed distribution.

Close Modal

or Create an Account

Close Modal
Close Modal